AlphaYou
Overview
Smart money at a glance
Filings to Oct 12, 2026Net buying: insiders sold $0 and bought $18K on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- +$18K netNet buying
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, latest quarter
- NoneNo large changes
Market overview
Fundamentals Aug 25- 52-wk high
- $0.40
- 52-wk low
- $0.00
- Beta
- 2.47
- Profit margin
- +0.0%
- Op margin
- -6649.0%
- ROE
- -548.0%
What do analysts expect?
No analyst estimates.
Questions about HUMAW filings
Are insiders buying or selling Humacyte Inc (HUMAW) stock?
Net buying: insiders sold $0 and bought $18K of HUMAW stock on the open market in the 90 days to Oct 12, 2026, according to SEC Form 4 filings. The largest was Jones, Keith Anthony (Director), who bought $18K. The latest filing was on Aug 19, 2026.
Which members of Congress have traded HUMAW recently?
None. No member of Congress disclosed a HUMAW trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this HUMAW smart-money data?
This summary uses filings available on Oct 12, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
1 fund holds a position and insiders have been net buying.
What insiders are doing
Buys (3)
- JK
Jones Keith Anthony
$18K
bought
- SK
Sebelius Kathleen
$50K
bought
- CM
Constantino Michael T.
$10K
bought
How top traders are positioned
No tracked top-trader positions in HUMAW right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Results versus expectations
No earnings history.
What the street expects next
Financials
What it sold, what it cost, what was left.
| USD | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $301.0K | $753.0K | $467.0K | $495.0K |
| Cost of what it sold | $2.1M | $2.1M | $10.9M | $2.0M |
| Gross profit | -$1.8M | -$1.4M | -$10.4M | -$1.5M |
| What it spent | ||||
| Research and development | $22.0M | $17.3M | $14.6M | $19.5M |
| Sales and admin | $7.8M | $7.6M | $23.0M | $7.9M |
| Other operating costs | -$1.9M | -$1.9M | -$17.2M | — |
| Total operating expenses | $28.0M | $23.0M | $20.4M | $27.4M |
| What was left | ||||
| Operating profit | -$29.7M | -$24.4M | -$30.8M | -$28.9M |
| Interest on debt | $2.5M | $2.6M | $3.1M | $2.3M |
| Profit before tax | -$37.7M | -$17.5M | -$24.8M | -$17.6M |
| Net profit | -$37.7M | -$17.5M | -$24.8M | -$17.6M |
| EBITDA | -$33.3M | -$13.0M | -$19.9M | -$13.6M |
Technicals
Price structure
Market data unavailable.